ドーパミナージックニューロンのエネルギー貯蔵の神経調節制御
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。ドーパミンは脳中部のニューロンに グリコーゲンを貯蔵するよう信号を送り 代謝ストレスに対する回復力を提供します この信号やグリコゲンへのアクセスの喪失は脆弱性を高め,パーキンソン病の神経退化に潜在的に貢献します.
科学分野
- 神経科学
- 細胞の代謝
- 神経変性疾患
背景
- 脳 特に中脳ドーパミンニューロンは 代謝的に非常に脆弱です
- これらのニューロンはパーキンソン病 (PD) に関与しており,バイオエネルギー欠損と関連があると考えられています.
- 関連酵素の存在にもかかわらず,神経細胞におけるエネルギー貯蔵庫としてのグリコゲンの役割は不明である.
研究 の 目的
- 中脳ドーパミナージックニューロンのグリコゲン可用性の調節を調査する.
- ドーパミンのシグナル伝達が ニューロンのエネルギーホメオスタシスに 果たす役割を調べるため
- 神経保護とパーキンソン病の病原性への影響を調査する.
主な方法
- 中脳ドーパミナージックニューロン培養
- ドーパミン自己受容体 (D2R) 信号伝達経路の調査
- 低代謝状態での神経機能の評価
主要な成果
- ドーパミンはD2Rを介して作用し,ドーパミナージックニューロンのグリコゲン貯蔵をシグナルする.
- グライコゲン貯蔵庫の存在は,代謝ストレス中に神経機能に有意な回復力を与えます.
- ドーパミン信号の喪失や グリコゲンへのアクセス障害は ニューロンを燃料不足に過敏にします
結論
- ドーパミンのように 局所的なエネルギー代謝を制御します
- グライコゲンは 中脳ドーパミンニューロンの 重要な燃料供給源です
- ドーパミンのシグナル伝達が低下し,その後のグリコゲン貯蔵量が減少すると,パーキンソン病における神経変性への感受性が増加する可能性があります.
関連する概念動画
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
The cephalic phase is a conditioned or learned response to familiar foods. Our appetite or desire for a particular food modifies the preparatory responses directed by the brain. Individuals may produce more saliva and stomach...
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...